دورية أكاديمية
Consensus on pharmacological treatment of obesity in Latin America.
| العنوان: | Consensus on pharmacological treatment of obesity in Latin America. |
|---|---|
| المؤلفون: | Cappelletti AM; Favaloro University, Buenos Aires, Argentina.; Argentine Society of Nutrition, Buenos Aires, Argentina., Valenzuela Montero A; Chilean Society of Obesity, Santiago de Chile, Chile., Cercato C; Endocrinology and Metabology Service, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil., Duque Ossman JJ; Colombian Association of Endocrinology, Diabetes and Metabolism, Armenia, Colombia., Fletcher Vasquez PE; Latinamerican Federation of Endocrinology, Panama City, Panama., García García JE; Salvador Zubiran National Institute of Medical Sciences and Nutrition, Tlalpan, Mexico., Mancillas-Adame LG; University Hospital and Medical School, Autonomous University of Nuevo León, Monterrey, Mexico., Manrique HA; Peruvian Society of Endocrinology, Lima, Peru., Ranchos Monterroso FM; Guatemalan Association of Endocrinology, Metabolism and Nutrition, Guatemala City, Guatemala., Segarra P; Ecuadorian Society of Endocrinology, Quito, Ecuador.; Ecuadorian Society of Internal Medicine, Quito, Ecuador., Navas T; General Hospital 'Dr. José Gregorio Hernandez', Los Magallanes, Caracas, Venezuela. |
| المصدر: | Obesity reviews : an official journal of the International Association for the Study of Obesity [Obes Rev] 2024 Apr; Vol. 25 (4), pp. e13683. Date of Electronic Publication: 2023 Dec 20. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Publishing Country of Publication: England NLM ID: 100897395 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1467-789X (Electronic) Linking ISSN: 14677881 NLM ISO Abbreviation: Obes Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2002->: Oxford, UK : Blackwell Publishing Original Publication: Oxford, UK : Blackwell Science, c2000- |
| مواضيع طبية MeSH: | Obesity*/drug therapy, Humans ; Consensus ; Latin America/epidemiology ; Surveys and Questionnaires ; Body Weight |
| مستخلص: | A panel of 10 experts in obesity from various Latin American countries held a Zoom meeting intending to reach a consensus on the use of anti-obesity medicines and make updated recommendations suitable for the Latin American population based on the available evidence. A questionnaire with 16 questions was developed using the Patient, Intervention, Comparison, Outcome (Result) methodology, which was iterated according to the modified Delphi methodology, and a consensus was reached with 80% or higher agreement. Failure to reach a consensus led to a second round of analysis with a rephrased question and the same rules for agreement. The recommendations were drafted based on the guidelines of the American College of Cardiology Foundation/American Heart Association Task Force on Practice. This panel of experts recommends drug therapy in patients with a body mass index of ≥30 or ≥27 kg/m 2 plus at least one comorbidity, when lifestyle changes are not enough to achieve the weight loss objective; alternatively, lifestyle changes could be maintained while considering individual parameters. Algorithms for the use of long-term medications are suggested based on drugs that increase or decrease body weight, results, contraindications, and medications that are not recommended. The authors concluded that anti-obesity treatments should be individualized and multidisciplinary. (© 2023 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.) |
| References: | Legetic B, Medici A, Hernández-Avila M, Alleyne G, Hennis A (Eds). Economic Dimensions of Non-communicable Disease in Latin America and the Caribbean. Disease Control Priorities. Companion Volume. 3rd ed. PAHO; 2016. Obesidad y sobrepeso. Who.int. [citado el 9 de octubre de 2021]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/obesity-and-overweight. WHO Consultation on Obesity (1997: Geneva, Switzerland), World Health Organization, Division of Noncommunicable Diseases & World Health Organization. Programme of Nutrition, Family and Reproductive Health. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization; 1998. Barquera S, Hernández-Barrera L, Trejo-Valdivia B, Shamah T, Campos-Nonato I, Rivera-Dommarco J. Obesidad en México, prevalencia y tendencias en adultos. Ensanut 2018-19 [Obesity in Mexico, prevalence and trends in adults. Ensanut 2018-19.]. Salud Publica Mex. 2020;62(6):682-692. doi:10.21149/11630. Peña M, Bacallao J (Eds). Obesity and Poverty: A New Public Health Challenge. PAHO; 2000. Scientific Pub:576. https://iris.paho.org/handle/10665.2/4007. Holub CK, Elder JP, Arredondo EM, et al. Obesity control in Latin American and U.S. Latinos: a systematic review. Am J Prev Med. 2013;44(5):529-537. doi:10.1016/j.amepre.2013.01.023 PMID: 23597819; PMCID: PMC4808744. Allison DB, Downey M, Atkinson RL, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008;16(6):1161-1177. doi:10.1038/oby.2008.231 Epub 2008 May 8. PMID: 18464753. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33(3):289-295. doi:10.1038/ijo.2009.2 Epub 2009 Feb 3. PMID: 19188927. Cappelletti AM. El enigma de la obesidad. En Cappelletti, Katz y colaboradores. Obesidad Encrucijadas y abordajes. Editorial Akadia; 2017. Caterson ID, Alfadda AA, Auerbach P, et al. Gaps to bridge: misalignment between perception, reality, and actions in obesity. Diabetes Obes Metab. 2019;21(8):1914-1924. doi:10.1111/dom.13752 Epub 2019 May 3. PMID: 31032548; PMCID: PMC6767048. Org.ar. Cited October 13, 2021. Available from: https://sanutricion.org.ar/wp-content/uploads/2022/01/Posicion-SAN-Obesidad-2020.pdf. Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485-497. doi:10.1038/s41591-020-0803-x Epub 2020 Mar 4. PMID: 32127716; PMCID: PMC7154011. Obesity. Who.int. [citado el 10 Oct 2021]. Disponible en: https://www.who.int/health-topics/obesity. Tsai AG. Integrating obesity treatment into routine primary care. Ann Intern Med. 2019;171(11):847-848. doi:10.7326/M19-2988 Epub 2019 Nov 12. PMID: 31711100. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102-S138. doi:10.1161/01.cir.0000437739.71477.ee. Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients With Obesity. Endocr Pract. 2016;22(Suppl 3):1-203. doi:10.4158/EP161365.GL Epub 2016 May 24. PMID: 27219496. Yumuk V, Tsigos C, Fried M, et al. Obesity Management Task Force of the European Association for the Study of Obesity. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402-424. doi:10.1159/000442721 Epub 2015 Dec 5. Erratum in: Obes Facts. 2016;9(1):64. PMID: 26641646; PMCID: PMC5644856. Apovian CM, Aronne LJ, Bessesen DH, et al. Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. doi:10.1210/jc.2014-3415 Epub 2015 Jan 15. Erratum in: J Clin Endocrinol Metab 2015 May;100(5):2135-2136. PMID: 25590212. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707. Durrer Schutz D, Busetto L, Dicker D, et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12(1):40-66. doi:10.1159/000496183 Epub 2019 Jan 23. PMID: 30673677; PMCID: PMC6465693. Pedersen SD, Manjoo P, Wharton S. Canadian Adult Obesity Clinical Practice Guidelines: Pharmacotherapy in Obesity Management. Accessed October 24, 2021. Available from: https://obesitycanada.ca/guidelines/pharmacotherapy. Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: the Obesity Society 2018 Position Statement. Obesity (Silver Spring). 2019;27(1):7-9. doi:10.1002/oby.22378 PMID: 30569641. Rosero RJ, Polanco JP, Ciro V, Uribe A, Manrique H, Sánchez PE. Proposal for a multidisciplinary clinical approach to obesity. J Med - Clin Res & Rev. 2020;4(12):1-11. doi:10.33425/2639-944x.1185. Gossmann M, Butsch WS, Jastreboff AM. Treating the chronic disease of obesity. Med Clin North am. 2021;105(6):983-1016. doi:10.1016/j.mcna.2021.06.005 PMID: 34688422. Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(2):213-265. doi:10.1016/j.jacc.2012.09.025 PMID: 31298150. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014;38(2):292-298. doi:10.1038/ijo.2013.74. Franke KB, Psaltis PJ. Coronary vasospasm induced by phentermine. Mayo Clin Proc. 2019 Jul;94(7):1138-1140. doi:10.1016/j.mayocp.2019.05.021 PMID: 31272562. Lucchetta RC, Riveros BS, Pontarolo R, et al. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clinics (Sao Paulo). 2017;72(5):317-324. doi:10.6061/clinics/2017(05)10 Erratum in: Clinics (Sao Paulo) 2018 Mar 15;73: e1err. PMID: 28591345; PMCID: PMC5439101. Cercato C, Roizenblatt VA, Leança CC, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond). 2009;33(8):857-865. doi:10.1038/ijo.2009.124. Soto-Molina H, Pizarro-Castellanos M, Rosado-Pérez J, et al. Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial. Int J Clin Pharmacol Ther. 2015;53(7):541-549. doi:10.5414/CP202135 PMID: 26073353. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308. doi:10.3945/ajcn.111.024927 Epub 2011 Dec 7. PMID: 22158731; PMCID: PMC3260065. Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther. 2008;14(2):120-142. doi:10.1111/j.1527-3458.2008.00041 x. PMID: 18482025; PMCID: PMC6494007. Hernández-Bastida A. Fentermina y topiramato contra fentermina más placebo en pacientes con sobrepeso u obesidad clase I o II. Med Int Méx. 2015;31:125-136. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended release in obese adults. Obesity (Silver Spring). 2013;21(11):2163-2171. doi:10.1002/oby.20584 Epub 2013 Oct 17. PMID: 24136928. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352. doi:10.1016/S0140-6736(11)60205-5 Epub 2011 Apr 8. Erratum in: Lancet. 2011 Apr 30;377(9776):1494. PMID: 21481449. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342. doi:10.1038/oby.2011.330 Epub 2011 Nov 3. PMID: 22051941; PMCID: PMC3270297. Greenway FL, Fujioka K, Plodkowski RA, et al. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi:10.1016/S0140-6736(10)60888-4 Epub 2010 Jul 29. Erratum in: Lancet. 2010 Aug 21;376(9741):594. Erratum in: Lancet. 2010 Oct 23;376(9750):1392. PMID: 20673995. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-4029. doi:10.2337/dc13-0234. NICE. Naltrexone-Bupropion for Managing Overweight and Obesity (TA494). 2017. Available from: www.nice.org.uk/guidance/ta494. Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646-667. doi:10.1111/bcp.14210 Epub 2020 Feb 4. PMID: 31918448; PMCID: PMC7098870. Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone/bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016;6(5):305-312. doi:10.1111/cob.12157 Epub 2016 Aug 1. PMID: 27477337; PMCID: PMC5129540. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-943. doi:10.1002/oby.20309 PMID: 23408728; PMCID: PMC3739931. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120. doi:10.1038/oby.2010.147 Epub 2010 Jun 17. PMID: 20559296; PMCID: PMC4459776. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. doi:10.1038/ijo.2013.120 Epub 2013 Jul 1. Erratum in: Int J Obes (Lond). 2013 Nov;37(11):1514. Erratum in: Int J Obes (Lond). 2015 Jan;39(1):187. PMID: 23812094. Lean ME, Carraro R, Finer N, et al. NN8022-1807 Investigators. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(5):689-697. doi:10.1038/ijo.2013.149 Epub 2013 Aug 14. PMID: 23942319; PMCID: PMC4010971. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843-854. doi:10.1038/ijo.2011.158 Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012 Jun;36(6):890. Erratum in: Int J Obes (Lond). 2013 Feb;37(2):322. PMID: 21844879; PMCID: PMC3374073. Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug des Devel Ther. 2015;30(9):1867-1875. doi:10.2147/DDDT.S58459 PMID: 25848222; PMCID: PMC4386791. Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28(3):529-536. doi:10.1002/oby.22726 PMID: 32090517; PMCID: PMC7065111. Kolotkin RL, Gabriel Smolarz B, Meincke HH, Fujioka K. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clin Obes. 2018;8(1):1-10. doi:10.1111/cob.12226 Epub 2017 Oct 16. PMID: 29045079; PMCID: PMC5813214. van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186-4196. doi:10.2337/db14-0849 Epub 2014 Jul 28. PMID: 25071023. Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab. 2016;18(5):491-499. doi:10.1111/dom.12639 Epub 2016 Mar 1. PMID: 26833744; PMCID: PMC5069568. Hernández DC, Monroy DC, Porras A. Eficacia y seguridad de liraglutida para la disminución de peso en adultos: revisión sistemática. Rev Col De Endocrinología, Diabetes Y Metabolismo. 2020;7(4):250-257. doi:10.53853/encr.7.4.651. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Jama. 2015;314(7):687-699. doi:10.1001/jama.2015.9676 Erratum in: JAMA. 2016 Jan 5;315(1):90. PMID: 26284720. Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085-1093. doi:10.2337/dc19-1745 Epub 2020 Mar 5. PMID: 32139381; PMCID: PMC7171937. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. doi:10.1038/ijo.2016.52 Epub 2016 Mar 23. PMID: 27005405; PMCID: PMC4973216. Alruwaili H, Dehestani B, le Roux CW. Clinical impact of liraglutide as a treatment of obesity. Clin Pharm. 2021;13:53-60. doi:10.2147/CPAA.S276085 PMID: 33732030; PMCID: PMC7958997. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 PMID: 26132939. Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128. doi:10.1056/NEJMoa1916038 Epub 2020 Mar 31. PMID: 32233338. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. doi:10.1002/oby.22794. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0 Epub 2021 Mar 2. PMID: 33667417. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. Jama. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224 PMID: 33755728; PMCID: PMC7988425. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4. Blundell J, Finlayson G, Axelsen M, et al. Effects of once weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932 Epub 2017 May 5. PMID: 28266779; PMCID: PMC5573908. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. doi:10.3389/fendo.2021.645563. Wilding JPH, Batterham RL, Calanna S, et al. Once weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. Di Francesco V, Sacco T, Zamboni M, et al. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study. Ann Nutr Metab. 2007;51(1):75-81. doi:10.1159/000100824. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111-2120. doi:10.1056/NEJMoa050156. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):523-530. doi:10.1111/j.1463-1326.2011.01554.x. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-1199. doi:10.1136/bmj.39385.413113.25. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917. doi:10.1056/NEJMoa1003114. Dedov II, Melnichenko GA, Troshina EA, Mazurina NV, Galieva MO. Body weight reduction associated with the sibutramine treatment: overall results of the PRIMAVERA primary health care trial. Obes Facts. 2018;11(4):335-343. doi:10.1159/000488880. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161. doi:10.2337/diacare.27.1.155. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs. 2004;64(24):2845-2864. doi:10.2165/00003495-200464240-00010. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care. 2004;27(1):33-40. doi:10.2337/diacare.27.1.33. Derosa G, Cicero AFG, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes: orlistat on insulin resistance. J Clin Pharm Ther. 2012;37(2):187-195. doi:10.1111/j.1365-2710.2011.01280.x. Gorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F. Effectiveness, and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR Study. Int J Clin Pract. 2019;73(11):e13399. doi:10.1111/ijcp.13399. Balcázar M, Cañizares S, Caicedo A, León Fierro A, Zambrano K. Protocolo de diagnóstico y manejo multidisciplinario de pacientes adultos con sobrepeso y obesidad en la consulta ambulatoria. Bitácora académica USFQ, 2021;9:1. Available from: https://revistas.usfq.edu.ec/index.php/bitacora/issue/view/182/134. Benziger CP, Bernabé-Ortiz A, Gilman RH, et al. Metabolic abnormalities are common among South American Hispanics subjects with normal weight or excess body weight: the CRONICAS cohort study. PLoS ONE. 2015;10(11):e0138968. doi:10.1371/journal.pone.0138968 PMID: 26599322; PMCID: PMC4658165. Catenacci VA, Hill JO, Wyatt HR. The obesity epidemic. Clin Chest Med. 2009;30(3):415-444, vii. doi:10.1016/j.ccm.2009.05.001 PMID: 19700042. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer-viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798. doi:10.1056/NEJMsr1606602 PMID: 27557308; PMCID: PMC6754861. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546. doi:10.7326/0003-4819-142-7-200504050-00012 PMID: 15809465. Erlandson M, Ivey LC, Seikel K. Update on office-based strategies for the management of obesity. Am Fam Physician. 2016;94(5):361-368. PMID: 27583422. Brauer P, Gorber SC, Shaw E, et al. Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. CMAJ. 2015;187(3):184-195. doi:10.1503/cmaj.140887 Epub 2015 Jan 26. PMID: 25623643; PMCID: PMC4330141. Bersoux S, Byun TH, Chaliki SS, Poole KG. Pharmacotherapy for obesity: what you need to know. Cleve Clin J Med. 2017;84(12):951-958. doi:10.3949/ccjm.84a.16094 PMID: 29244650. Alarcón-Sotelo A, Gómez-Romero P, De Regules-Silva S, et al. Up to date in the long-term pharmacological treatment of obesity. A therapeutic option? Med Int Mex. 2018;34(6):946-958. Ferreira-Hermosillo A, Salame-Khouri L, Cuenca-Abruch D. Tratamiento farmacológico de la obesidad [Pharmacological treatment of obesity]. Rev Med Inst Mex Seguro Soc. 2018;56(4):395-409. Spanish. PMID: 30521744. Alvarez V. Tratamiento farmacológico de la obesidad. Rev médica Clín Las Condes. 2012;23(2):173-179. doi:10.1016/s0716-8640(12)70295-x. Tassinari D, Giovanelli A, Asteria C. Obesity: medical and surgical treatment. In: Luzi L, ed. Thyroid, Obesity and Metabolism. Springer; 2021. Italy:131-175. doi:10.1007/978-3-030-80267-7. Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):ITC33-ITC48. doi:10.7326/AITC201903050. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020;16(3):177-189. doi:10.1038/s41574-019-0310-7. Batsis JA, Zagaria AB. Addressing obesity in aging patients. Med Clin North am. 2018;102(1):65-85. doi:10.1016/j.mcna.2017.08.007 Epub 2017 Oct 21. PMID: 29156188; PMCID: PMC5724972. Aschner P, Buendía R, Brajkovich I, et al. Determination of the cutoff point for waist circumference that establishes the presence of abdominal obesity in Latin American men and women. Diabetes Res Clin Pract. 2011;93(2):243-247. doi:10.1016/j.diabres.2011.05.002 Epub 2011 May 31. PMID: 21632141. Medina-Lezama J, Pastorius CA, Zea-Diaz H, et al. Optimal definitions for abdominal obesity and the metabolic syndrome in Andean Hispanics: the PREVENCION study. Diabetes Care. 2010;33(6):1385-1388. doi:10.2337/dc09-2353 Epub 2010 Mar 3. PMID: 20200303; PMCID: PMC2875461. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology, and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513-537. doi:10.1038/s41574-018-0062-9 PMID: 30065268; PMCID: PMC6241236. Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P. Diabetes and sarcopenic obesity: pathogenesis, diagnosis, and treatments. Front Endocrinol (Lausanne). 2020;11:568. doi:10.3389/fendo.2020.00568 PMID: 32982969; PMCID: PMC7477770. Romero-Corral A, Somers VK, Sierra-Johnson J. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond). 2008;32(6):959-966. doi:10.1038/ijo.2008.11. Bray GA, Kim KK, JPH W, World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723. doi:10.1111/obr.12551 Epub 2017 May 10. PMID: 28489290. Suissa K, Schneeweiss S, Kim DW, Patorno E. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. Diabetes Obes Metab. 2021;23(7):1542-1551. doi:10.1111/dom.14367 Epub 2021 Mar 25. PMID: 33651454. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring). 2009;17(9):1730-1735. doi:10.1038/oby.2009.69 Epub 2009 Mar 19. PMID: 19300434. Kadeli DK, Sczepaniak JP, Kumar K, Youssef C, Mahdavi A, Owens M. The effect of preoperative weight loss before gastric bypass: a systematic review. J Obes. 2012;2012:867540. doi:10.1155/2012/867540 Epub 2012 Jun 7. PMID: 22720139; PMCID: PMC3376766. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obes Rev. 2012;13(6):509-517. doi:10.1111/j.1467-789X.2011.00972.x Epub 2011 Dec 29. PMID: 22212682. Hall KD, Kahan S. Maintenance of lost weight, and long-term management of obesity. Med Clin North am. 2018;102(1):183-197. doi:10.1016/j.mcna.2017.08.012 PMID: 29156185; PMCID: PMC5764193. Thomas JG, Bond DS, Phelan S, Hill JO, Wing RR. Weight-loss maintenance for 10 years in the National Weight Control Registry. Am J Prev Med. 2014;46(1):17-23. doi:10.1016/j.amepre.2013.08.019 PMID: 24355667. Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10(2):81-89. doi:10.1007/s13679-021-00425-1 Epub 2021 Jan 25. PMID: 33492629. Edgerton C, Mehta M, Mou D, Dey T, Khaodhiar L, Tavakkoli A. Patterns of weight loss medication utilization and outcomes following bariatric surgery. J Gastrointest Surg. 2021;25(2):369-377. doi:10.1007/s11605-020-04880-4 Epub 2021 Jan 8. PMID: 33420652. Velapati SR, Shah M, Kuchkuntla AR, et al. Weight regain after bariatric surgery: prevalence, etiology, and treatment. Curr Nutr Rep. 2018;7(4):329-334. doi:10.1007/s13668-018-0243-0 PMID: 30168043. Gazda CL, Clark JD, Lingvay I, Almandoz JP. Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes. Obesity (Silver Spring). 2021;29(5):829-836. doi:10.1002/oby.23146 Epub 2021 Apr 4. Erratum in: Obesity (Silver Spring). 2021 Sep;29(9):1567. PMID: 33818009. Wharton S, Kamran E, Muqeem M, Khan A, Christensen RAG. The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review. J Drug Assess. 2019;8(1):184-191. doi:10.1080/21556660.2019.1678478 PMID: 33110683; PMCID: PMC7567517. Stanford FC. Controversial issues: a practical guide to the use of weight loss medications after bariatric surgery for weight regain or inadequate weight loss. Surg Obes Relat Dis. 2019;15(1):128-132. doi:10.1016/j.soard.2018.10.020 Epub 2018 Oct 30. PMID: 30527889; PMCID: PMC6441616. Gutt S, Schraier S, González Bagnes MF, Yu M, González CD, Di Girolamo G. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother. 2019;20(8):939-947. doi:10.1080/14656566.2019.1583746. Schiavon CA, Bhatt DL, Ikeoka D. Three-year outcomes of bariatric surgery in patients with obesity and hypertension. A randomized clinical trial. Ann Intern Med. 2020;173(9):685-693. doi:10.7326/M19-3781. Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10(1):14-30. doi:10.1007/s13679-020-00422-w Epub 2021 Jan 6. PMID: 33410104; PMCID: PMC7787121. Lee PC, Dixon J. Pharmacotherapy for obesity. Aust Fam Physician. 2017;46(7):472-477. PMID: 28697290. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39(2):79-132. doi:10.1210/er.2017-00253 PMID: 29518206; PMCID: PMC5888222. Anekwe CV, Knight MG, Seetharaman S, Dutton WP, Chhabria SM, Stanford FC. Pharmacotherapeutic options for weight regain after bariatric surgery. Curr Treat Options Gastroenterol. 2021;19(3):524-541. doi:10.1007/s11938-021-00358-7 Epub 2021 Jul 16. PMID: 34511864; PMCID: PMC8425280. Kato K, Matsushita A, Suzuki S, Sai H, Hirabayashi H, Hattori R. Drug-induced cystitis caused by herbal medicine (Bofutsushosan). Urol Case Rep. 2021;38:101644. doi:10.1016/j.eucr.2021.101644 PMID: 33850729; PMCID: PMC8024595. Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. Herbal medicine for depression and anxiety: a systematic review with assessment of potential psycho-oncologic relevance. Phytother Res. 2018;32(5):865-891. doi:10.1002/ptr.6033 Epub 2018 Feb 21. PMID: 29464801; PMCID: PMC5938102. Farzaei MH, Bayrami Z, Farzaei F, et al. Poisoning by medical plants. Arch Iran Med. 2020;23(2):117-127. PMID: 32061075. Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140(3):513-518. doi:10.1016/j.jep.2012.01.051 Epub 2012 Feb 9. PMID: 22342381. Babos MB, Heinan M, Redmond L, et al. Herb-drug interactions: worlds intersect with the patient at the center. Medicines (Basel). 2021;8(8):44. doi:10.3390/medicines8080044 PMID: 34436223; PMCID: PMC8401017. Batsis JA, Apolzan JW, Bagley PJ, et al. A systematic review of dietary supplements and alternative therapies for weight loss. Obesity (Silver Spring). 2021;29(7):1102-1113. doi:10.1002/oby.23110 PMID: 34159755; PMCID: PMC8231729. Maunder A, Bessell E, Lauche R, Adams J, Sainsbury A, Fuller NR. Effectiveness of herbal medicines for weight loss: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(6):891-903. doi:10.1111/dom.13973. Kidambi S, Batsis JA, Donahoo WT, et al. Dietary supplements, and alternative therapies for obesity: a perspective from The Obesity Society's Clinical Committee. Obesity (Silver Spring). 2021;29(7):1095-1098. doi:10.1002/oby.23189. Jairoun AA, Al-Hemyari SS, Shahwan M, Zyoud SH. Adulteration of weight loss supplements by the illegal addition of synthetic pharmaceuticals. Molecules. 2021;26(22):6903. doi:10.3390/molecules26226903. Wierzejska RE. Dietary supplements-for whom? The current state of knowledge about the health effects of selected supplement use. Int J Environ Res Public Health. 2021;18(17):8897. doi:10.3390/ijerph18178897. Lai S, Yu C, Dennehy CE, Tsourounis C, Lee KP. Online marketing of ephedra weight loss supplements: labeling and marketing compliance with the U.S. Food and Drug Administration ban on ephedra. J Altern Complement Med. 2021;27(9):796-802. doi:10.1089/acm.2021.0016. Lua PL, Roslim NA, Ahmad A, Mansor M, Aung MMT, Hamzah F. Complementary and alternative therapies for weight loss: a narrative review. J Evid Based Integr Med. 2021;26:2515690X211043738. doi:10.1177/2515690X211043738. Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016;387(10031):1947-1956. doi:10.1016/S0140-6736(16)00271-3. Verhaegen AA, Van Gaal LF. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. J Endocrinol Invest. 2017;40(11):1165-1174. doi:10.1007/s40618-017-0719-6. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population-based cohort study. BMJ. 2018;361:k1951. doi:10.1136/bmj.k1951. Arterburn D, Sofer T, Boudreau DM, et al. Long-term weight change after initiating second-generation antidepressants. J Clin Med. 2016;5(4):E48. doi:10.3390/jcm5040048. |
| معلومات مُعتمدة: | Adium Pharma |
| فهرسة مساهمة: | Keywords: Latin America; obesity; pharmacotherapy; weight management |
| تواريخ الأحداث: | Date Created: 20231220 Date Completed: 20240319 Latest Revision: 20240319 |
| رمز التحديث: | 20240319 |
| DOI: | 10.1111/obr.13683 |
| PMID: | 38123524 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1467-789X |
|---|---|
| DOI: | 10.1111/obr.13683 |